Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. - Wikidata - awgldk - TriplyDB

Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial.

Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial.

http://www.wikidata.org/entity/Q34647669

about

Digitalis for treatment of heart failure in patients in sinus rhythm Digoxin-associated mortality: a systematic review and meta-analysis of the literature Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort Emergency department visits and hospitalizations for digoxin toxicity: United States, 2005 to 2010 Chronic Heart Failure Clinical Practice Guidelines' Class 1-A Pharmacologic Recommendations: Start-to-End Synergistic Drug Therapy?Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial.Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure.Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure A perspective on re-evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile.The vulnerable phase after hospitalization for heart failure.Is foxglove effective in heart failure?Contemporary Controversies in Digoxin Use in Systolic Heart Failure.International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial.Digoxin and 30-Day All-Cause Readmission in Long-Term Care Residents Hospitalized for Heart Failure.Current Drug Therapy in Chronic Heart Failure: the New Guidelines of the European Society of Cardiology (ESC).Progress or lack of progress in hospitalized heart failure.Drug treatment of heart failure in the elderly.The EJHF last Editor's legacy: how can a high impact factor be built?Ivabradine in heart failure: NICE guidance.Outpatient management of chronic heart failure.Targeting digoxin dosing to serum concentration: is the bullseye too small?Essential Opposite Roles of ERK and Akt Signaling in Cardiac Steroid-Induced Increase in Heart Contractility.The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.Improving Postdischarge Outcomes in Acute Heart Failure Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction†

P2860

Q24194992-7F92ABB5-9962-463D-A716-30B3420781DB Q27026975-8C87B195-1D78-49EC-9C5F-D2609A47126B Q35035016-C9B71630-1ECE-48F1-9F38-8C7F2D528FC9 Q35789263-AD25101C-894F-4F56-8F14-A03D97A39E19 Q36419969-A883C5F8-7D7D-4A3F-A38D-A247BB2060B7 Q36661094-8C68E205-23DC-45F2-A111-67D9996D527D Q36860117-C7F3F98F-D272-4C6C-8973-151C126B0D84 Q37588012-23BFDB96-F7A7-482C-8AF9-00E22B522E0C Q37594550-25B651A8-6BB3-48B5-92FE-28B36143FDEE Q38191517-65CE0698-EB0D-4FD8-BC25-F164B97057F9 Q38349760-95BA2C69-331A-4687-A445-F2465A791093 Q38449921-B53AD213-F861-4395-917C-F6EFE74B4BDE Q38970521-384A02A9-CA8E-486C-B39F-45682F48EF29 Q39202662-B3970DF4-8C32-42BC-A2A1-689AE7E3B85A Q40202565-CDF1325C-F76F-479B-A1D0-382DB95EFB68 Q41686268-6245B38D-99E3-4E33-B3D1-A3F16F24C1C8 Q45904891-328F9BE5-AAEF-4945-818B-B43E9F826A10 Q50014420-5A13FE21-6327-4D0F-95EE-66CB58D08D94 Q50584662-35A107E8-E181-450F-A951-299DD10163CF Q50895487-206E5A11-DA8E-4C6A-B457-E0A905A77882 Q50998627-059BE32C-4DD0-4CCF-8C89-6F566C32D53C Q54445922-28E6BF4F-697C-47A8-8F8B-B7410ECF937F Q55027100-E41E43E1-F232-4FA7-A149-9E7E3F7EDD10 Q55078568-F7FBCD5B-1933-42CD-BE1A-C29F3DE97464 Q57628371-6C260A64-17F4-4380-9D1B-C5F8845132A1 Q57628656-EC7386F8-FF50-44F5-B71E-6889A26476DB

P2860

Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial.

http://www.wikidata.org/entity/Q34647669

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Effect of oral digoxin in high ...... oup analysis of the DIG trial.

@ast

Effect of oral digoxin in high ...... oup analysis of the DIG trial.

@en

Effect of oral digoxin in high ...... oup analysis of the DIG trial.

@nl

type

label

Effect of oral digoxin in high ...... oup analysis of the DIG trial.

@ast

Effect of oral digoxin in high ...... oup analysis of the DIG trial.

@en

Effect of oral digoxin in high ...... oup analysis of the DIG trial.

@nl

prefLabel

Effect of oral digoxin in high ...... oup analysis of the DIG trial.

@ast

Effect of oral digoxin in high ...... oup analysis of the DIG trial.

@en

Effect of oral digoxin in high ...... oup analysis of the DIG trial.

@nl

P1433

Q34647669-B72B2952-BB2C-4505-BA73-889AC6B6705E

P1476

Q34647669-8539BF0F-C30A-49E6-A669-D8159C645EEF

P2093

Q34647669-01EF5D99-4AFC-41D4-B38B-00B134CF7D53

Q34647669-0F0CCA18-1954-4FCE-B280-43DA0EC72DE3

Q34647669-40DD1B8B-DA71-496B-80F9-0C4B2BA4F977

Q34647669-CB8A6CCD-1C47-4939-9590-037C42D6AC40

Q34647669-DA45211D-B5AE-4D7D-A6FE-6109158FCC7C

Q34647669-E5D4F7B4-E4BE-4FDC-9758-E194DBBE0738

P2860

Q34647669-06215730-6D9E-4C39-8067-23F58DB82856

Q34647669-0F3411C7-3EFC-4C3D-8609-D64DA488AE57

Q34647669-1140E521-0003-4F6D-96AF-7C3B3D0B71ED

Q34647669-47525407-67EA-4E6D-86A1-3BFA08D4E14B

Q34647669-53BA0F32-7B19-4FC5-A47F-1E4390C52910

Q34647669-5BA8F8D8-B78E-47B6-A81E-BC8A76B4B0F5

Q34647669-70991DA6-DCDE-4484-AE32-5159076A564D

Q34647669-7C3BF0EE-95AD-4C1A-BB05-1E62FC8C61FB

Q34647669-881249A7-F10E-4F13-9D05-C8589305B36B

Q34647669-8D1AD36E-47ED-4B84-BFE1-5F52238BE0A7

P304

Q34647669-BB10BA7E-B918-40D3-98EE-28CECCC506FB

P31

Q34647669-E4BF61B1-7BE7-4C43-9CDC-CAE5C6749ABC

P356

Q34647669-2E23E198-E248-4B8F-90B8-8B00AA94851C

P433

Q34647669-035C7A23-FD77-43B1-919B-0A231A2AB22B

P478

Q34647669-DE431CD0-3501-4932-9B11-DBDF7BB6A132

P50

Q34647669-1FB7670E-D6C5-44EB-838A-B31E94904281

Q34647669-47A00F1D-EC92-4CA2-BB6A-C1E75EF65D44

Q34647669-7E62A599-2922-451E-87B0-02D33A60F5F6

Q34647669-8CFE202F-5241-44AD-8883-666FACB3E944

Q34647669-DDF7E129-F8A0-4736-8498-C72FF7529AEC

Q34647669-E2CCACE7-674B-41DD-8432-C209F3D67242

P577

Q34647669-4CB8C23D-40ED-446D-A844-85A67958D2FC

P5875

Q34647669-019C5126-7DF8-4FF1-9BC0-D48B80AA04E1

P698

Q34647669-3E6F71F9-4FBE-4596-B81D-DF9ADDE2A521

P921

Q34647669-2A54F14B-5D3C-4CC5-B437-517CCB4AFC4E

Q34647669-9C7B8C47-09F5-40D3-B991-B320CECF0630

Q34647669-D4216304-E0BF-46B0-A30B-D08FA4A34FDA

P932

Q34647669-82D6E630-57D7-4A01-8C7A-492ABC290F54

P356

P1433

European Journal of Heart Failure

P1476

Effect of oral digoxin in high ...... oup analysis of the DIG trial.

@en

P2093

Inmaculada B Aban

http://www.w3.org/2001/XMLSchema#string

John G F Cleland

http://www.w3.org/2001/XMLSchema#string

John J V McMurray

http://www.w3.org/2001/XMLSchema#string

Kanan Patel

http://www.w3.org/2001/XMLSchema#string

Kirkwood F Adams

http://www.w3.org/2001/XMLSchema#string

Stephen J Greene

http://www.w3.org/2001/XMLSchema#string

P2860

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: de

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial.

Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group.

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial.

Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

P304

551-559

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURJHF/HFT010

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Stefan D. Anker

Mihai Gheorghiade

Gerasimos Filippatos

Dirk J van Veldhuisen

P577

2013-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235376772

http://www.w3.org/2001/XMLSchema#string

P698

23355060

http://www.w3.org/2001/XMLSchema#string

P921

P932

3707428

http://www.w3.org/2001/XMLSchema#string